Intraparty disagreements over mifepristone cause pause in spending bill agreement until August recess ends; Officials urge the FDA to regulate cannabidiol as a dietary supplement; State medical boards tasked with protecting Americans frequently failed to stop doctors for COVID-19 misinformation.
Republican Disagreements Halt Spending Bill
Intraparty friction over the abortion pill mifepristone have delayed a plan for House votes on Friday and led GOP heads to push legislation funding the FDA until August recess ends, reported The Hill. The spending bill would also fund the Department of Agriculture and contains a provision to constrict restrictions surrounding access to mifepristone, which would nullify the agency’s decision to permit the drug to be dispensed through mail and retail pharmacies.
Officials Urge FDA to Regulate Cannabidiol
Officials and hemp advocates pressed the FDA to quickly regulate cannabidiol (CBD) products as dietary supplements at a House subcommittee hearing Thursday, according to Bloomberg Law. CBD products can’t be sold or regulated as dietary supplements yet because of CBD’s intrinsic risk profile and currently incomplete risk-management resources. Customer safeguards in the Federal Food, Drug and Cosmetic Act would apply to CBD products if they were regulated as dietary supplements, including adverse event reporting and possible child-proof packaging requirements.
Doctors Spreading COVID-19 Misinformation Rarely Punished
Doctors who endangered patients’ lives by pushing medical misinformation during the COVID-19 pandemic and its aftermath have not encountered sufficient repercussions, according to a Washington Post analysis of disciplinary records from medical boards in every state, reported The Washington Post. These medical boards, assigned with protecting the American public, frequently failed to stop doctors who went against medical consensus and prescribed treatments not approved for COVID-19 or who misled patients about masks and vaccines, found the investigation. Presently, no organization monitors how many doctors have been punished for spreading COVID-19 misinformation.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Eliminating Enhanced PTCs Would Have Cascading Economic Impacts, Report Estimates
March 6th 2025Enhanced premium tax credits (PTCs) have made marketplace health insurance more affordable, and eliminating them could have sweeping impacts on consumers and the health care industry, according to a new report.
Read More
Senate Questions NIH Nominee on Funding, Transparency, and COVID-19 Impact
March 5th 2025Jay Bhattacharya, MD, PhD, defended his vision for the National Institutes of Health in a Senate committee confirmation hearing, tackling concerns on research funding, public trust, and scientific integrity.
Read More